SeekingAlpha · Mar 5, 2026
CR
NASDAQ · CRMD
CorMedix Inc.
Healthcare · Biotechnology
$7.83
Up+$0.01 (+0.10%)
Updated Sep 14, 2026, 7:09 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 924.2M
- P/E ratio
- 5.48
- Dividend yield
- 0.00%
- 52-week range
- $6.14 – $9.09
- Volume
- 820.99K
- Avg. volume
- 2.73M
Price performance
CRMD price history
1M range · 19 trading sessions · Daily adjusted prices
CRMD closed at $7.83 after 19 trading sessions, up 2.02% for the selected period.
- Last close
- $7.83
- Period change
- +2.02%
- Period low
- $7.67
- Period high
- $8.61
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $8.04 | $8.06 | $7.82 | $7.825 | 820.99K |
| Sep 10, 2026 | $8.11 | $8.12 | $7.92 | $7.96 | 857.26K |
| Sep 9, 2026 | $8.18 | $8.33 | $8.08 | $8.13 | 928.24K |
| Sep 8, 2026 | $8.28 | $8.37 | $8.11 | $8.18 | 1.1M |
| Sep 4, 2026 | $8.45 | $8.605 | $8.31 | $8.43 | 792.91K |
| Sep 3, 2026 | $8.69 | $8.745 | $8.43 | $8.47 | 707.67K |
| Sep 2, 2026 | $8.40 | $8.62 | $8.33 | $8.61 | 1.1M |
| Sep 1, 2026 | $8.25 | $8.49 | $8.18 | $8.38 | 880.48K |
| Aug 31, 2026 | $8.26 | $8.29 | $8.06 | $8.26 | 980.54K |
| Aug 28, 2026 | $8.28 | $8.395 | $8.185 | $8.30 | 780.22K |
| Aug 27, 2026 | $8.49 | $8.49 | $8.2803 | $8.31 | 707.59K |
| Aug 26, 2026 | $8.60 | $8.605 | $8.37 | $8.39 | 865.51K |
| Aug 25, 2026 | $8.35 | $8.575 | $8.28 | $8.56 | 1.24M |
| Aug 24, 2026 | $8.28 | $8.495 | $8.18 | $8.28 | 1.01M |
| Aug 21, 2026 | $8.29 | $8.41 | $8.155 | $8.20 | 1.5M |
| Aug 20, 2026 | $8.49 | $8.5449 | $8.19 | $8.23 | 1.01M |
| Aug 19, 2026 | $8.30 | $8.53 | $8.11 | $8.52 | 1.47M |
| Aug 18, 2026 | $7.71 | $8.27 | $7.71 | $8.17 | 2.03M |
| Aug 17, 2026 | $7.55 | $8.11 | $7.4801 | $7.67 | 2.17M |
Latest CRMD news
The latest Smart Investors Daily articles mentioning CRMD.
Stock researchCompany · Overview
CRMD research
Overview
Company profile and research snapshot.
Company profile
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| Apr 28, 2026 | RBC Capital | Outperform | — |
| Apr 28, 2026 | Leerink Partners | Outperform | — |
| Apr 28, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Mar 5, 2026
CorMedix Inc (NASDAQ:CRMD) Shares Drop on Q4 2025 Earnings Miss
CorMedix reports strong Q4 2025 revenue growth but misses EPS estimates, leading to a sharp pre-market stock decline.
Benzinga · Mar 5, 2026
CorMedix shares are trading lower after the company reported mixed Q4 financial results.
Benzinga · Mar 5, 2026
CORRECTION: Cormedix Affirms FY2026 Sales Guidance of $300.000M-$320.000M
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $300.000 million-$320.000 million to $300.000 million-$320.000 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
